Please ensure Javascript is enabled for purposes of website accessibility

Could Biogen Acquire Axsome Therapeutics?

By Keith Speights – Aug 20, 2021 at 6:01AM

Key Points

  • Axsome's neurological pipeline appears to be a good fit for Biogen.
  • After its major stock decline this year, Axsome's price tag would be quite affordable.
  • Biogen needs a deal due to challenges for its existing product lineup and a relatively weak late-stage pipeline.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here are three reasons why a buyout just might happen.

It's been a great year for Biogen (BIIB 4.72%). The big biotech won a controversial U.S. approval for its Alzheimer's disease drug Aduhelm. Because of this surprising victory, Biogen's shares have soared close to 40% year to date.

The story hasn't been so great, though, for Axsome Therapeutics (AXSM 2.05%). The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS-05 in treating major depressive disorder. Axsome stock plunged on the news and is now down more than 70% this year.

But Axsome's pipeline still has plenty of potential. And Biogen seems likely to look for smaller drugmakers to gobble up. Could Biogen acquire Axsome? There are three reasons why the answer could be a resounding "yes."

A person drawing a chalk picture on a wall of a big yellow fish with its mouth open near a small yellow fish.

Image source: Getty Images.

A good fit

The most important reason why Axsome could be on Biogen's radar is that it seems to be a pretty good fit for the big biotech. Biogen focuses primarily on neurological disorders. So does Axsome.

Biogen first rose to success with its multiple sclerosis (MS) franchise. Its spinal muscular atrophy drug Spinraza achieved blockbuster sales. Aduhelm will likely become one of the best-selling drugs on the market as a treatment for Alzheimer's disease.

The company's pipeline includes nearly 30 candidates. Most of them target neurological disorders, from additional experimental Alzheimer's disease therapies to stroke.

Axsome is somewhat unusual for a clinical-stage biotech in that it has two lead candidates. The company had hoped to win FDA approval for AXS-05 in treating major depressive disorder this month, although that's unlikely now with the agency's review of deficiencies in Axsome's regulatory filing. Axsome filed for FDA approval of another drug, AXS-07, in treating migraines in the second quarter of this year.

In addition to these two programs, Axsome is evaluating AXS-05 in a late-stage study targeting Alzheimer's disease agitation. It hopes to advance the drug into a late-stage study as a smoking-cessation therapy. The company should soon initiate a late-stage study of AXS-12 in treating narcolepsy. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia.

Attractive price

There aren't many positives when a biotech stock crashes more than 70%. However, such a meltdown does make a company much cheaper for a potential acquisition.

That's certainly the case for Axsome. The company's market cap is now below $800 million. With multiple late-stage programs that could win FDA approvals in the not-too-distant future, Axsome could be viewed as a bottom-barrel bargain. This assumes, of course, that its pipeline candidates still have reasonable prospects for approvals.

Biogen should be able to buy Axsome on the cheap if it chose to do so. The company could definitely afford the deal. Biogen ended the second quarter with a cash stockpile of nearly $4 billion. As Aduhelm picks up sales momentum, the company's cash position will likely improve significantly.

Biogen needs a deal 

Prior to the FDA approval of Aduhelm, Biogen was in a position where it desperately needed to make an acquisition or significant licensing deal. Sales for its MS franchise continue to decline. Spinraza isn't the growth driver that it once was. Rituxan, which Biogen licensed to Roche, faces biosimilar competition. 

It probably wouldn't be correct to say that Biogen is now desperate to make a deal with the FDA approval of Aduhelm. However, the drug seems likely to face some stiff challenges winning acceptance.

Some healthcare providers have stated they won't prescribe the drug. Some payers, including the Veterans Administration, have refused to include Aduhelm on their formularies.

Other Alzheimer's disease drugs could be on the way that might threaten Aduhelm. Eli Lilly, for example, plans to file for FDA approval for its Alzheimer's disease drug donanemab by the end of this year.

Meanwhile, Biogen doesn't have an especially strong late-stage pipeline. With all of these dynamics, it would make a lot of sense for the company to look to make an acquisition that could quickly provide sales growth. There aren't many small drugmakers around that would enable Biogen to accomplish this goal. But Axsome would if at least one or two of its late-stage programs win FDA approval.

Biogen might not have its eye on Axsome -- but it wouldn't be surprising if it does.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Stock Quote
$305.17 (4.72%) $13.76
Eli Lilly And Stock Quote
Eli Lilly And
$371.08 (1.96%) $7.13
Roche Holding Ltd. (ADR) Stock Quote
Roche Holding Ltd. (ADR)
$40.92 (0.64%) $0.26
Axsome Therapeutics Stock Quote
Axsome Therapeutics
$72.29 (2.05%) $1.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.